MetaVia pairs slim liver-fat data with $8.8m cash as it maps 2027 trials

MetaVia has published an investor presentation, dated November 2026, setting out how it intends to advance two liver-focused cardiometabolic assets. The commercial question it raises is less about the science than about whether a company with $8.8m in cash at 30 September 2026 can fund the studies it describes.

The deck includes interim Part 3B results for DA-1726, with liver fat down by roughly 68% and placebo-adjusted weight loss of 13.5%. The data come from a tiny group of patients, so they indicate direction rather than a reliable estimate of how the drug will perform in larger trials.

For vanoglipel, which MetaVia is developing in MASH (metabolic dysfunction-associated steatohepatitis), the company has Phase 2a results and plans to consult the FDA on a combination with resmetirom. The meeting is slated for the second half of 2026, and a combination Phase 2a study is pencilled in for the first half of 2027. By way of context, resmetirom is the approved MASH therapy marketed by Madrigal as Rezdiffra; that detail is not drawn from the deck. For DA-1726, MetaVia intends to start a Phase 2 trial in MetALD and ALD, the conditions linked to metabolic dysfunction with alcohol use and to alcohol-related liver disease, in the second half of 2027.

The material reviewed does not say how long the $8.8m will last or how the trials will be paid for. Nor does it list the five catalysts its title promises through early 2027. Those gaps leave the company's runway, and any role for outside capital or partners, unresolved.